Cybrexa Therapeutics

Cybrexa Therapeutics is developing a novel therapy that directly targets the tumor microenvironment. Founded by physician-scientists and an experienced management team, Cybrexa has established numerous successful life science ventures. Cybrexa Therapeutics is a platform technology company focused on oncology, dedicated to achieving antigen-dependent and antigen-independent targeting of tumors through deep tissue penetration of small-molecule anticancer drugs. We are passionate about bringing new treatment options to help more cancer patients live longer and more fulfilling lives. Cybrexa alphalex is a tumor-targeting platform that powers new applications and combinations with existing cancer therapies. Using an elegant approach for targeted intracellular drug delivery independent of surface antigens, alphalex selectively delivers potent anticancer agents directly to tumor cells.